January 19, 2023 Oakville, Ontario – January 19, 2023: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink: NMDBF) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for a reverse merger transaction with Lancaster Lithium Inc. (“Lancaster Lithium”) as previously announced on December 14, 2022, the… Read More »NeonMind Announces Consolidation
January 11, 2023 Oakville, Ontario – January 11, 2023: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announces that, in preparation for the reverse merger transaction with Lancaster Lithium Inc. previously announced on December 14, 2022, NeonMind has cancelled an aggregate of 3,742,500… Read More »NeonMind Announces Cancellation of Securities
December 14, 2022 Oakville, Ontario – December 14, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) is pleased to announce that it has signed a binding letter agreement dated December 14, 2022 with Lancaster Lithium Inc. (“Lancaster Lithium”) whereby the parties have… Read More »NeonMind Signs Agreement to complete Reverse Merger with Lancaster Lithium Inc.
December 9, 2022 Oakville, Ontario – December 9, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTC Pink:NMDBF) (FSE:6UF) (“NeonMind” or the “Company”) announced today that Rob Tessarolo, a director on the NeonMind Board of Directors, was appointed Chief Executive Officer and President on December 7, 2022.… Read More »NeonMind Announces Management Change
November 8, 2022 3:45PM EDT Oakville, Ontario – November 8, 2022: NeonMind Biosciences Inc. (CSE: NEON) (FRA:6UF0) (“NeonMind” or the “Company”) announced the strategic decision to seek to divest its lead drug development program NEO-001 and undertake a search for a new business acquisition. Its… Read More »NeonMind Announces Decision to Seek A Buyer For Drug Development Program
May 30, 2022 6:00pm EDT Oakville, Ontario – May 30, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF0) (“NeonMind” or the “Company”) announced today that has made changes to its Management, Board of Directors and Advisory Board to support the Company’s strategic plans. Effective… Read More »NeonMind Announces Organizational Changes
April 21, 2021 8:00am EDT Engages Thrive Health, a Leading Digital Patient Care Platform to Streamline Care Programs and Data Collection OAKVILLE, ON / ACCESSWIRE / April 21, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), announced today it has advanced its strategy to… Read More »NeonMind To Improve Patient Care and Data Management by Adopting Digital Platform for Ketamine Treatments in Preparation of Opening Its Inaugural Specialty Mental Health Clinic
April 11, 2021 8:00am EDT Initiates Medical Adoption Program with Impetus Digital, a Leading Healthcare Platform for Virtual Medical Education OAKVILLE, ON / ACCESSWIRE / April 19, 2022 / NeonMind Biosciences Inc. (CSE:NEON)(OTCQB:NMDBD)(FRA:6UF) (“NeonMind” or the “Company“), an integrated drug development and wellness company focused on… Read More »NeonMind Engages Leading Digital Platform for Medical Education and Adoption of Ketamine Treatments in Preparation of Opening its Inaugural Specialty Mental Health Clinic
April 11, 2021 8:00am EDT Partnered with SRx Health Solutions and BioScript Solutions to Build Out a Network of NeonMind-branded Specialty Mental Health Clinics Across Canada Oakville, Ontario – April 12, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”), an integrated drug… Read More »NeonMind Announces Plan to Launch 10 Clinics for Innovative Treatments as Mental Health Crisis Grows
April 11, 2021 8:00am EDT Oakville, Ontario – April 11, 2022: NeonMind Biosciences Inc. (CSE: NEON) (OTCQB: NMDBF) (FRA: 6UF) (“NeonMind” or the “Company”) an integrated drug development and wellness company focused on bringing innovative psychedelic-based treatments to people suffering from obesity and mental health disorders,… Read More »NeonMind Announces Share Consolidation
English